| Document |
Document Title |
|
WO/2024/050500A1 |
Combined administration of a selective glucocorticoid receptor modulator (SGRM; e.g., relacorilant or exicorilant) and a cancer therapeutic (e.g., a taxane or antiandrogen) is useful for identifying elevated cortisol activity in patients...
|
|
WO/2024/046471A1 |
The present application provides a class of novel compounds having a USP1 inhibitory activity as shown in formula (II'), pharmaceutical compositions comprising the compounds, useful intermediates for preparing the compounds, and a method...
|
|
WO/2024/046420A1 |
The present disclosure relates to a fused bicyclic compound, and a preparation method therefor and the use thereof in medicine. Specifically, the present disclosure relates to a fused bicyclic compound as shown in general formula (I), a ...
|
|
WO/2024/046929A1 |
This invention provides a method of modifying a cyanobacterial or fungal toxin for use as a payload in an antibody-drug conjugate, comprising the following steps: selecting a cyanobacterial or fungal toxin having a base structure known t...
|
|
WO/2024/049348A1 |
The present invention provides a modified immune cell, which comprises a T cell receptor (TCR) capable of specifically targeting hepatitis B surface antigen (HBsAg) and a chimeric conversion receptor. The chimeric conversion receptor use...
|
|
WO/2024/050318A1 |
In one aspect, disclosed herein are novel multimeric costimulatory agonistic constructs comprising said monomers for expanding tumor infiltrating lymphocytes (TILs) in vitro or ex vivo said methods comprising obtaining TILs and culturing...
|
|
WO/2024/050524A1 |
Provided herein are compositions for increasing Apolipoprotein L1 (ApoL1) in target cells. The ApoL1 can be a recombinant protein or an endogenous protein optionally in a ApoL1-containing complex. Antibodies and other binding molecules t...
|
|
WO/2023/160569A9 |
This disclosure relates to compounds of Formula (I) as PGE2 receptor antagonists or a pharmaceutically acceptable salt thereof.
|
|
WO/2024/049926A1 |
Disclosed herein are methods for treating cancer comprising administering to a subject a daily dose of Compound A, or a pharmaceutically acceptable salt thereof, in combination with a CDK4/6 inhibitor.
|
|
WO/2024/047172A1 |
The present invention relates to an integrin alpha10 antibody drug conjugate and medical uses thereof.
|
|
WO/2024/048478A1 |
Disclosed is a novel treatment method in which the effectiveness of cancer treatment is improved by using an immune checkpoint regulator in combination. An anticancer drug according to the present invention has, as an active ingredient, ...
|
|
WO/2024/048615A1 |
The present invention provides a method for producing a compound represented by formula (I), the method including a step that reacts a compound represented by formula (II) with a compound represented by formula (III).
|
|
WO/2024/048644A1 |
This carrier for delivering a target substance to MUC6 expression-negative cancer tissues contains a molecule having the activity of binding to mannose. The cancer tissues may be MUC6 expression-negative gastric cancer tissues arising fr...
|
|
WO/2024/050370A1 |
The present disclosure relates to compounds of Formula (I): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are usef...
|
|
WO/2024/045414A1 |
The present invention provides a heptamethine cyanine dye-artemisinin conjugate and use thereof, and belongs to the technical field of cancer therapy. The heptamethine cyanine dye-artemisinin conjugate provided by the present invention c...
|
|
WO/2024/046389A1 |
The present invention relates to a combination therapy, comprising an anti-TIGIT antibody or an antigen-binding fragment thereof and an anti-CTLA-4 antibody or an antigen-binding fragment thereof. The present invention also relates to co...
|
|
WO/2024/046246A1 |
Use of a mitoxantrone liposome and capecitabine in treating nasopharyngeal carcinoma, in particular recurrent and/or metastatic nasopharyngeal carcinoma. The present invention further provides a method for treating nasopharyngeal carcino...
|
|
WO/2024/048541A1 |
This medicament, which contains, together or separately in combination with a CDK inhibitor, an antibody or a fragment thereof having an immunological reactivity with a CAPRIN-1 protein, is useful for treating and/or preventing cancer.
|
|
WO/2024/050366A1 |
Described herein are methods, devices, and systems for identifying a subset of a plurality of features, using one or more feature importance metrics, for training and using a homologous repair deficiency (HRD) classification model. Furth...
|
|
WO/2024/048555A1 |
The present invention relates to a therapeutic or prophylactic drug, a combination, a pharmaceutical composition, a preparation, a therapeutic or prophylactic method, and a growth suppressor for ALK fusion gene-positive cancer having tem...
|
|
WO/2024/049161A1 |
The present invention relates to a novel antibody or an antigen-binding fragment thereof, which specifically binds to PD-L1, a chimeric antigen receptor comprising an antigen-binding variable fragment of the antibody, immune cells expres...
|
|
WO/2024/046168A1 |
Provided are a Lactobacillus brevis strain and anti-cervical cancer use thereof. The provided Lactobacillus brevis is specifically (Lactobacillus brevis) YNH, which is deposited under CGMCC No. 24368 at the China General Microbiological ...
|
|
WO/2024/050517A1 |
This invention relates to methods of producing reprogrammed B cells, methods of treating cancer, and methods of enhancing an immune response in a subject having, suspected to have and/or at risk of cancer. The invention further relates t...
|
|
WO/2024/050342A1 |
Methods of treating prostate cancer, including castration-resistant prostate cancer and metastatic castration-resistant prostate cancer, comprising administering an effective amount of an androgen receptor (AR) antagonist and an effectiv...
|
|
WO/2024/050399A1 |
Single-domain antibodies that specifically bind human papillomavirus (HPV) E6 or E7 oncogenic peptides in complex with human major histocompatibility complex (MHC) proteins are described. The E6-MHC-specific and E7-MHC-specific single-do...
|
|
WO/2024/048657A1 |
Provided is a method for treating lymphoma. The present invention uses a pharmaceutical composition that is for treating lymphoma and comprises BCV, a pharmaceutically acceptable salt thereof, or a solvate of these. The lymphoma may be E...
|
|
WO/2024/048490A1 |
[Problem] It is desired to develop a molecule that maintains antitumor activity and offers excellent safety. It is also desired to develop an antibody-drug conjugate that can be administered systemically and delivers a STING agonist spec...
|
|
WO/2024/046622A1 |
The invention lies in the field of delivery of nucleic acids into a cell. In particular, disclosed herein is a nucleic acid that is polyplexed with a polymeric scaffold, which is provided in combination with an endosomal escape-enhancing...
|
|
WO/2024/049792A1 |
A method of treating cancer in a subject is provided, the method including administering to the subject a therapeutic amount of a composition including phosphatidylglycerol nanovesicles (NVs). A method of inhibiting M2 macrophage polariz...
|
|
WO/2024/047114A1 |
Disclosed herein are recombinant non-oncolytic viruses, for example adenoviruses, that encode bispecific T cell engagers (BiTE's). These BiTE's can be expressed at any desired site of the human body. The non-oncolytic viruses are able to...
|
|
WO/2024/049922A1 |
Disclosed herein are methods for treating cancer comprising administering to a subject a daily dose of Compound A, or a pharmaceutically acceptable salt thereof, as a single agent.
|
|
WO/2024/046443A1 |
Provided herein are macrocyclic compounds, pharmaceutical compositions, and methods of using related to cyclin dependent kinases (CDKs). The compounds herein are selective CDK2 inhibitors, which can be used for treating cancer.
|
|
WO/2024/050297A1 |
Described herein are compounds that are inhibitors of autophagy and their use in the treatment of disorders such as cancers.
|
|
WO/2024/050515A1 |
The present disclosure relates to methods of treating prostate cancer in a subject by co-administering to the subject an effective amount of: (i) an androgen receptor signaling inhibitor (ARSI) (e.g., abiraterone); and (ii) an anti-Trop-...
|
|
WO/2024/047218A1 |
Described herein are compositions and methods to produce masked antibodies useful in a variety of therapeutic indications.
|
|
WO/2024/046405A1 |
Provided is use of a compound represented by formula (I) or a pharmaceutically acceptable salt thereof in treating advanced or metastatic NSCLC.
|
|
WO/2024/047130A1 |
Relaxin-2 for use as a broad-spectrum substitute of glucocorticoids, mineralocorticoids, corticosteroids and their analogues for treating tissue and endothelial injuries without incurring inducing gluconeogenesis, Cushing's syndrome and ...
|
|
WO/2024/047110A1 |
The present invention relates to a new method to obtain more effective CAR-T cells. Here, the inventors worked on the function of FOXO1 in T lymphocyte physiology for many years. They recently described, using a FOXO1 pharmacological inh...
|
|
WO/2024/050296A2 |
The present disclosure is directed to methods of inhibiting clonal hematopoiesis in a subject by administering a senolytic agent.
|
|
WO/2024/046327A1 |
Compounds represented by formula I, and racemates, stereoisomers, tautomers, isotope-labeled substances, nitrogen oxides, solvates, polymorphs, pharmaceutically acceptable salts or prodrugs thereof. The compounds have a good inhibition e...
|
|
WO/2024/046332A1 |
Provided is a pharmaceutical composition, comprising: (a) a targeting agent against cancer cell mitochondria, (b) an ion chelating agent, and (c) a pharmacologically active multivalent ion. On the basis of the total weight of the pharmac...
|
|
WO/2024/050351A1 |
Described herein are compounds that are inhibitors of autophagy and their use in the treatment of disorders such as cancers.
|
|
WO/2024/049306A1 |
This disclosure provides compounds, including chemical conjugates, and compositions comprising these, as well as kits, which are useful in therapeutic and diagnostic procedures, amongst others. This disclosure also provides preparative m...
|
|
WO/2024/050396A1 |
The disclosure provides methods of treating cancers that have activating FGFR3 gene alterations by administering a compound of Formula (I) as disclosed herein, or a pharmaceutically acceptable salt of a compound of Formula (I).
|
|
WO/2024/048687A1 |
The present invention provides a pharmaceutical composition that contains an MYT1 inhibitor as an active ingredient, that is for therapy or prevention of cancer in a patient exhibiting RB1 functional deterioration, and that is to be used...
|
|
WO/2024/046406A1 |
Provided herein are certain alkylidenyl carbamate compounds that inhibit certain K-Ras proteins and are therefore useful for the treatment of cancers mediated by such proteins. Also provided are pharmaceutical compositions containing suc...
|
|
WO/2024/046370A1 |
The present invention relates to compounds of formula (I) and formula (II), or pharmaceutically acceptable salts, prodrugs, tautomers, or stereoisomers and solvates thereof. Said compounds can be used for the treatment of cancers and inf...
|
|
WO/2024/049220A1 |
The present invention relates to an immunoconjugate or a pharmaceutically acceptable salt thereof characterized in that a camptothecin-based drug (A) is bound, through a linker (C), to: an antibody or an antigen-binding fragment (B-1) th...
|
|
WO/2024/045503A1 |
Disclosed is a TRKA (G667C), FLT3 and FLT3 (D835Y) target inhibitor N-[4-(6-fluoro-1H-2-benzimidazolyl)benzyl]-(E)-3-(3-pyridine
)acrylamide as shown in formula (I), a preparation method therefor, a pharmaceutical composition containing ...
|
|
WO/2024/050267A1 |
The present disclosure is directed to oligonucleotide dendrons comprising an oligonucleotide stem linked to one or more oligonucleotide branches. The disclosure also provides methods of using the oligonucleotide dendrons.
|
